# US 2013/0157978 A1 · Preparation for the prevention and/or treatment of vascular disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157978 A1
- Document ID: US20130157978A1
- Status: Published application
- Kind: A1
- Application number: 13/767,730
- Filed: 2013-02-14
- Published: 2013-06-20
- Earliest claimed: 2000-05-08
- Assignees: N.V. Nutricia
- Inventors: Amanda Johanne Kiliaan; Robert Johan Joseph Hageman
- Web page: https://patentgrep.com/patent/US20130157978A1

## CPC

- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A23L 33/115: Fatty acids or derivatives thereof; Fats or oils
- A23L 33/15: Vitamins
- A23L 33/16: Inorganic salts, minerals or trace elements
- A61K 31/14: Quaternary ammonium compounds, e.g. edrophonium, choline (betaines A61K31/205)
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 31/205: Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 31/4415: Pyridoxine, i.e. Vitamin B6 (pyridoxal phosphate A61K31/675)
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/683: Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K 33/30: Zinc; Compounds thereof
- A61K 33/34: Copper; Compounds thereof
- A61K 36/16: Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/06: Antihyperlipidemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The present invention relates to a preparation suitable for the prevention and/or treatment of vascular disorders, comprising the following fractions: fraction a) consisting of long chain polyunsaturated fatty acids; fraction b) consisting of phospholipids, which fraction contains at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine. fraction c) consisting of compounds which are a factor in methionine metabolism, which fraction contains at least one member selected from the group consisting of folic acid, vitamin B12, vitamin B6, magnesium and zinc.

## Claims

### Claim 1

A method for treating a person suffering from or being at risk of degeneration of cerebral function, cognitive degeneration and/or dementia syndromes associated with vascular disorders; vascular degeneration of cerebral function, vascular cognitive degeneration, vascular dementia and/or Alzheimer's disease, said method comprising administering to said person a preparation, comprising:
a) long chain polyunsaturated fatty acid fraction comprising docosahexaenoic acid (DHA);
b) at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine; and
c) folic acid and vitamin B6, wherein the amount of folic acid is at least 200 μg per daily dosage.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said person suffering from or being at risk of degeneration of cerebral function, cognitive degeneration and/or dementia syndromes associated with vascular disorders is a person suffering from or being at risk of Alzheimer's disease, vascular dementia, presenile dementia, senile dementia, atherosclerotic dementia, Parkinson's and Huntington's disease.

### Claim 3 (depends on 1)

The method according to claim 1, further comprising choline and/or carnitine.

### Claim 4 (depends on 1)

The method according to claim 1, further comprising 1.5-30 g citrate and/or citric acid per daily dose.

### Claim 5 (depends on 4)

The method according to claim 4, comprising more than 2.4 g citrate and/or citric acid per daily dose.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the long chain polyunsaturated fatty acid (LCPUFA) fraction comprises omega-3 and omega-6 LCPUFAs in a ratio of omega-3: omega-6 LCPUFAs of 2.5 to 5.5 wt/wt.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the preparation comprises 50-2000 mg DHA or at least 120 mg DHA.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the preparation further comprises eicosapentaenoic acid (EPA).

### Claim 9 (depends on 1)

The method according to claim 1, wherein the preparation comprises 120-2000 mg per daily dosage of EPA and DHA collectively, of which at least 50 mg of the daily dosage is DHA.

### Claim 10 (depends on 1)

The method according to claim 1, wherein fraction a) further comprises linoleic acid (LA) and/or alpha-linolenic acid (ALA) and one omega-6 fatty acid selected from dihomogammlinolenic acid (DHGLA) and arachidonic acid (AA), and the ratio of the total amount of EPA+DHA+DHGLA+AA to the total amount of LA and ALA is larger than 0.4:1.

### Claim 11 (depends on 1)

The method according to claim 1, further containing vitamin C and/or vitamin E.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the amount of folic acid is at least 400 μg per daily dosage.

### Claim 13 (depends on 1)

The method according to claim 1, wherein vitamin B6 is included in an amount of more than 2 mg vitamin B6 per daily dose.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the preparation is a liquid, concentrate or powder.

### Claim 15

A preparation, comprising:
a) long chain polyunsaturated fatty acid fraction comprising omega-3 and omega-6 LCPUFAs in a ratio of omega-3: omega-6 LCPUFAs of 2.5 to 5.5 wt/wt, said fraction comprising docosahexaenoic acid (DHA) and optionally EPA;
b) at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine; and
c) folic acid and vitamin B6, wherein the amount of folic acid is at least 200 μg per daily dosage.

### Claim 16 (depends on 15)

The preparation according to claim 15, further comprising choline and/or carnitine.

### Claim 17 (depends on 15)

The preparation according to claim 15, further comprising 1.5-30 g citrate and/or citric acid per daily dose.

### Claim 18 (depends on 17)

The preparation according to claim 17, comprising more than 2.4 g citrate and/or citric acid per daily dose.

### Claim 19 (depends on 15)

The preparation according to claim 15, comprising 50-2000 mg DHA or at least 120 mg DHA.

### Claim 20 (depends on 15)

The preparation according to claim 15, comprising 120-2000 mg per daily dosage of EPA and DHA collectively, of which at least 50 mg of the daily dosage is DHA.

### Claim 21 (depends on 15)

The preparation according to claim 15, wherein fraction a) further comprises linoleic acid (LA) and/or alpha-linolenic acid (ALA) and one omega-6 fatty acid selected from dihomogammlinolenic acid (DHGLA) and arachidonic acid (AA), and the ratio of the total amount of EPA+DHA+DHGLA+AA to the total amount of LA and ALA is larger than 0.4:1.

### Claim 22 (depends on 15)

The preparation according to claim 15, further containing vitamin C and/or vitamin E.

### Claim 23 (depends on 15)

The preparation according to claim 15, wherein the amount of folic acid is at least 400 μg per daily dosage.

### Claim 24 (depends on 15)

The preparation according to claim 15, wherein vitamin B6 is included in an amount of more than 2 mg vitamin B6 per daily dose.

### Claim 25 (depends on 15)

The preparation according to claim 15, being a liquid, concentrate or powder.

### Claim 26

A method for treating a person suffering from or being at risk of vascular disorders or secondary disorders associated therewith, said method comprising administering to said person a preparation, comprising:
a) long chain polyunsaturated fatty acid fraction comprising docosahexaenoic acid (DHA) and optionally eicosapentaeonic acid (EPA);
b) at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine; and
c) folic acid and vitamin B6, wherein the amount of folic acid is at least 200 μg per daily dosage.
